Does Blue Cross Blue Shield Cover Tremfya for UC?

If you have ulcerative colitis and your gastroenterologist has prescribed Tremfya, the honest answer to whether Blue Cross Blue Shield covers it is that it depends entirely on which Blue plan you have. Blue Cross Blue Shield is a federation of more than 30 independent companies, each setting its own formulary, prior authorization rules, and step therapy requirements. There is no single national Blue Cross Tremfya policy. Tremfya, known generically as guselkumab, is an interleukin-23 inhibitor that the FDA approved for moderately to severely active ulcerative colitis, so most Blue plans do list it, but where it sits and what you must try first varies widely. This guide explains how to find your own plan's answer.

What Tremfya Is and Why Approval Matters

Tremfya is a biologic that blocks interleukin-23, a protein that drives inflammation in ulcerative colitis. The FDA approved guselkumab for adults with moderately to severely active ulcerative colitis, with the label describing both an intravenous induction option and a fully subcutaneous regimen for induction and maintenance, per the Tremfya prescribing information. The approval was supported by the QUASAR phase 3 program, in which 23 percent of guselkumab-treated patients reached clinical remission at induction week 12 compared with 8 percent on placebo. Because it is a newer entrant approved after long-established biologics, many Blue plans position it as a later-line option rather than a first choice, which is the central reason coverage feels inconsistent from one member to the next.

Why Blue Cross Coverage Varies So Much

Each independent Blue company contracts with its own pharmacy benefit manager, and that PBM shapes the formulary and the rules attached to a drug like Tremfya. Many Blue plans use Prime Therapeutics, which several Blue companies jointly own, and you can see Tremfya listed on Prime-administered drug lists such as the Blue Cross Blue Shield of Texas formulary. Other plans route specialty drugs through CarelonRx. The federal employee program maintains its own separate FEP Blue formulary. Because the benefit manager, the formulary tier, and the medical policy all differ by plan, two people who both carry a Blue Cross card can face completely different requirements for the same prescription. Treating any single plan's rule as universal is the most common mistake patients make.

Typical Prior Authorization and Step Therapy

Across most Blue plans, Tremfya for ulcerative colitis requires prior authorization, meaning your gastroenterologist must submit clinical documentation before the plan agrees to pay. Many plans also apply step therapy, requiring you to have failed or been unable to tolerate certain other treatments first. The specifics differ sharply. The Blue Cross Blue Shield of Mississippi ulcerative colitis policy lists Tremfya among preferred pharmacy agents and requires prior authorization, while the Blue Cross Blue Shield of North Dakota guselkumab policy requires a documented trial of a TNF inhibitor and Entyvio, plus a JAK inhibitor, before approval. Two Blue plans, two very different paths. Knowing which version applies to you is essential before you can predict approval.

How to Find Your Own Plan's Rules

You can locate your specific requirements without guessing. Start with the documents your plan publishes, then confirm details with member services.

• Find your plan's drug list, often called a formulary, on your Blue plan's website and search for Tremfya to see its tier and any restriction codes.

• Locate the medical or pharmacy policy for guselkumab on that same plan to read the exact prior authorization and step therapy criteria.

• Call the member services number on your card and ask whether Tremfya for ulcerative colitis needs prior authorization and what you must try first.

Reading the policy yourself matters because the restriction codes on a formulary, such as those marking prior authorization or step therapy, tell you what hurdles to expect before your doctor even submits paperwork.

Building the Medical Necessity Case and Appealing

If your plan requires step therapy, the strongest application documents exactly which ulcerative colitis treatments you have already tried, for how long, and why each was stopped, whether through inadequate response, loss of response, or intolerance. The QUASAR program enrolled patients who had failed conventional or advanced therapy, which mirrors the kind of history many Blue plans expect to see before approving guselkumab, per the QUASAR phase 3 induction and maintenance studies. A clear, dated treatment record lets your gastroenterologist match your history to the plan's published criteria. If the plan denies the request, you have the right to appeal, and a well-documented record of prior biologic failures and clinical findings is what overturns most denials. Persistence and precise documentation, aligned to your specific plan's policy, are what move a denial to an approval.

Conclusion

Whether Blue Cross Blue Shield covers Tremfya for ulcerative colitis has no single answer, because Blue Cross is dozens of independent plans with their own formularies, benefit managers, and step therapy rules. Tremfya is FDA approved for moderately to severely active ulcerative colitis and appears on most Blue formularies, but it usually sits behind prior authorization and often behind a requirement to fail other agents first. The reliable path is to read your own plan's drug list and guselkumab policy, confirm the rules with member services, and assemble a precise record of your prior ulcerative colitis treatments. That documentation is what satisfies prior authorization, supports an appeal, and ultimately determines whether your Blue plan pays for the medication your gastroenterologist chose.